2013-000052-17: Study to investigate the early prediction of toxicity following chemotherapy and differences in drug handling in Ewing's sarcoma patients |
|
|
| Ongoing | 4 | 120 | Europe | Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, Ifosfamide, Powder for solution for injection, Concentrate for solution for infusion, Solution for infusion, Solution for injection, Powder for concentrate for solution for infusion, Cyclophosphamide, Eposin, Doxorubicin Hydrochloride, Vincristine Sulphate, Ifosfamide | The Newcastle Upon Tyne Hospitals NHS Foundation Trust | Ewing sarcoma patients, Bone cancer, Diseases [C] - Cancer [C04] | | | | |
ChiCTR1900022667: A prospective randomized controlled trial for recombinant human thrombopoietin (rhTPO) at different intervening times to prevent and treat thrombocytopenia after chemotherapy with doxoburicin combined with isocyclophosphamide (AI) regimen in osteosarcoma and soft tissue sarcoma |
|
|
| Not yet recruiting | 4 | 96 | | The patients distributed in group A was treated with rhTPO immediately at a dose of 300 U.d-1.kg-1, ih. ;The patients distributed in group B continued to observe and check blood every other day. When platelets were found to be less than 75*109/L, rhTPO was administered subcutaneously at a dose of 300 U.d-1.kg-1 once a day. | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Beijing Xisike Clinical Oncology Research Foundation | Osteosarcoma and soft tissue sarcoma | | | | |
